Cargando…

Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge

Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against challenge. Follow up experiments indicated that pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo-Pinilla, Eva, de la Poza, Francisco, Gubbins, Simon, Mertens, Peter Paul Clement, Ortego, Javier, Castillo-Olivares, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125940/
https://www.ncbi.nlm.nih.gov/pubmed/25643968
http://dx.doi.org/10.1016/j.antiviral.2015.01.009
_version_ 1783516051401605120
author Calvo-Pinilla, Eva
de la Poza, Francisco
Gubbins, Simon
Mertens, Peter Paul Clement
Ortego, Javier
Castillo-Olivares, Javier
author_facet Calvo-Pinilla, Eva
de la Poza, Francisco
Gubbins, Simon
Mertens, Peter Paul Clement
Ortego, Javier
Castillo-Olivares, Javier
author_sort Calvo-Pinilla, Eva
collection PubMed
description Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against challenge. Follow up experiments indicated that passive transfer of antiserum, from MVA-VP2 immune donors to recipient mice 1 h before challenge, conferred complete clinical protection and significantly reduced viraemia. These studies have been extended to determine the protective effect of MVA-VP2 vaccine-induced antiserum, when administered 48 h before, or 48 h after challenge. In addition, passive transfer of splenocytes was undertaken to assess if they confer any degree of immunity to immunologically naïve recipient mice. Thus, antisera and splenocytes were collected from groups of mice that had been vaccinated with MVA-VP2, or wild type MVA (MVA-wt), for passive immunisation of recipient mice. The latter were subsequently challenged with AHSV-4 (together with appropriate vaccinated or unvaccinated control animals) and protection was assessed by comparing clinical signs, lethality and viraemia between treated and control groups. All antiserum recipients showed high protection against disease (100% survival rates even in mice that were immunised 48 h after challenge) and statistically significant reduction or viraemia in comparison with the control groups. The mouse group receiving splenocytes from MVA-VP2 vaccinates, showed only a 40% survival rate, with a small reduction in viraemia, compared to those mice that had received splenocytes from MVA-wt vaccinates. These results confirm the primarily humoral nature of protective immunity conferred by MVA-VP2 vaccination and show the potential of administering MVA-VP2 specific antiserum as an emergency treatment for AHSV.
format Online
Article
Text
id pubmed-7125940
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71259402020-04-08 Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge Calvo-Pinilla, Eva de la Poza, Francisco Gubbins, Simon Mertens, Peter Paul Clement Ortego, Javier Castillo-Olivares, Javier Antiviral Res Article Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against challenge. Follow up experiments indicated that passive transfer of antiserum, from MVA-VP2 immune donors to recipient mice 1 h before challenge, conferred complete clinical protection and significantly reduced viraemia. These studies have been extended to determine the protective effect of MVA-VP2 vaccine-induced antiserum, when administered 48 h before, or 48 h after challenge. In addition, passive transfer of splenocytes was undertaken to assess if they confer any degree of immunity to immunologically naïve recipient mice. Thus, antisera and splenocytes were collected from groups of mice that had been vaccinated with MVA-VP2, or wild type MVA (MVA-wt), for passive immunisation of recipient mice. The latter were subsequently challenged with AHSV-4 (together with appropriate vaccinated or unvaccinated control animals) and protection was assessed by comparing clinical signs, lethality and viraemia between treated and control groups. All antiserum recipients showed high protection against disease (100% survival rates even in mice that were immunised 48 h after challenge) and statistically significant reduction or viraemia in comparison with the control groups. The mouse group receiving splenocytes from MVA-VP2 vaccinates, showed only a 40% survival rate, with a small reduction in viraemia, compared to those mice that had received splenocytes from MVA-wt vaccinates. These results confirm the primarily humoral nature of protective immunity conferred by MVA-VP2 vaccination and show the potential of administering MVA-VP2 specific antiserum as an emergency treatment for AHSV. The Authors. Published by Elsevier B.V. 2015-04 2015-01-30 /pmc/articles/PMC7125940/ /pubmed/25643968 http://dx.doi.org/10.1016/j.antiviral.2015.01.009 Text en © 2015 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Calvo-Pinilla, Eva
de la Poza, Francisco
Gubbins, Simon
Mertens, Peter Paul Clement
Ortego, Javier
Castillo-Olivares, Javier
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title_full Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title_fullStr Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title_full_unstemmed Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title_short Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
title_sort antiserum from mice vaccinated with modified vaccinia ankara virus expressing african horse sickness virus (ahsv) vp2 provides protection when it is administered 48 h before, or 48 h after challenge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125940/
https://www.ncbi.nlm.nih.gov/pubmed/25643968
http://dx.doi.org/10.1016/j.antiviral.2015.01.009
work_keys_str_mv AT calvopinillaeva antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge
AT delapozafrancisco antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge
AT gubbinssimon antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge
AT mertenspeterpaulclement antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge
AT ortegojavier antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge
AT castilloolivaresjavier antiserumfrommicevaccinatedwithmodifiedvacciniaankaravirusexpressingafricanhorsesicknessvirusahsvvp2providesprotectionwhenitisadministered48hbeforeor48hafterchallenge